Back to top
more

Cencora, Inc. (COR)

(Real Time Quote from BATS)

$237.72 USD

237.72
367,433

-0.61 (-0.26%)

Updated Jun 26, 2024 02:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Shockwave Medical's (SWAV) Reducer Receives Positive Results

by Zacks Equity Research

Shockwave Medical (SWAV) announces the 'real-world' results of the REDUCER-I study, which is intended to collect long-term outcomes on Shockwave Reducer, a novel treatment for refractory angina.

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

by Zacks Equity Research

Investors are optimistic about Myriad Genetics' (MYGN) strong solvency position and improvement in testing volume.

Bruker (BRKR) Introduces Magnet Technology for NMR Adoption

by Zacks Equity Research

Bruker's (BRKR) latest novel technology facilitates the widespread application of NMR in academic basic and clinical research.

Silk Road Medical's (SILK) New Launch to Aid Its TCAR Portfolio

by Zacks Equity Research

Silk Road Medical (SILK) announces its latest launch of ENROUTE Transcarotid Neuroprotection System PLUS, which is likely to aid in TCAR procedures.

Here's Why You Should Retain Penumbra (PEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about Penumbra (PEN) on strength exhibited in the Thrombectomy business and global expansion.

Labcorp (LH) Extends MRD Clinical Research With New Launch

by Zacks Equity Research

Labcorp (LH) Plasma Detect MRD solution advances its leadership in precision oncology across the solid tumor oncology care continuum.

AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Despite strength in the Med Tech business, AngioDynamics (ANGO) registers overall soft performance in third-quarter fiscal 2024.

AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment

by Zacks Equity Research

AngioDynamics (ANGO) announces the FDA's approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.

Haemonetics' (HAE) New TEG 6s Cartridge Gets FDA Approval

by Zacks Equity Research

Haemonetics' (HAE) TEG testing gives vital information that can assist doctors with better control of their patients' hemostasis.

QIAGEN (QGEN) Boosts Cancer Research Suite With New Launches

by Zacks Equity Research

QIAGEN's (QGEN) new products, coupled with the IVD version of QIAGEN's digital PCR platform QIAcuity, are planned to be released in mid-2024.

GE HealthCare's (GEHC) New Launch to Enhance Cardiac Care

by Zacks Equity Research

GE HealthCare's (GEHC) latest offering is likely to expand access to cardiac care by enabling more medical professionals to be able to capture cardiac images.

Glaukos' (GKOS) iDose TR Receives Permanent J- Code From CMS

by Zacks Equity Research

Glaukos (GKOS) announces the receipt of a permanent J-code for iDose TR from the CMS, which is likely to boost the billing and payment process.

Reasons to Add Cardinal Health (CAH) to Your Portfolio Now

by Zacks Equity Research

Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

Here's Why You Should Add Ecolab (ECL) to Your Portfolio Now

by Zacks Equity Research

Ecolab's (ECL) focus on research and development raises optimism about the stock.

Cencora, Inc. (COR) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Veeva Systems (VEEV) Makes Change to Front Office (revised)

by Zacks Equity Research

Veeva Systems' (VEEV) CFO Brent Bowman steps down, leading analysts to weigh in on the impact and prospects for the cloud-solutions company.

Quest Diagnostics (DGX) Collaborates With Broad Clinical Labs

by Zacks Equity Research

Quest Diagnostics (DGX) collaboration is intended to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.

Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now

by Zacks Equity Research

PacBio's (PACB) strong product demand and top-line growth raise optimism about the stock.

QuidelOrtho's (QDEL) QuickVue Gets FDA Nod for COVID Testing

by Zacks Equity Research

QuidelOrtho (QDEL) announces the FDA's approval of QuickVue, which is likely to be used for convenient and accurate COVID-19 pathogen testing.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

Veeva Systems' (VEEV) CFO Resignation Sparks 6% Stock Drop

by Zacks Equity Research

Veeva Systems' (VEEV) CFO, Brent Bowman, steps down, causing a 6% stock price decline. Analysts weigh in on the impact and prospects for the cloud-solutions company.

Baxter's (BAX) Latest FDA Approval to Boost Infusion Therapy

by Zacks Equity Research

Baxter's (BAX) Novum IQ Infusion Platform is likely to help enhance patient safety and efficiency for clinicians following the FDA's clearance.

Here's Why Investors Should Retain Labcorp (LH) Stock for Now

by Zacks Equity Research

Investors are optimistic about Labcorp (LH) on the continued strength of Central Labs, which is driving the success of the biopharma segment.

Three Reasons to Retain Avanos (AVNS) Stock in Your Portfolio

by Zacks Equity Research

Avanos' (AVNS) strong product line and focus on R&D raise optimism about the stock.

Abbott's (ABT) i-STAT TBI Cartridge Receives FDA Approval

by Zacks Equity Research

Abbott's (ABT) i-STAT Alinity instrument uses whole blood to help assess patients with a suspected mild traumatic brain injury or concussion.